Lansson Pharmaceutical

Lansson Pharmaceutical is a clinical-stage biopharmaceutical group based in China that specializes in the development and commercialization of treatments for Central Nervous System (CNS) disorders, anesthesia, and emergency medicine. The company follows a dual-track strategy, focusing on both innovative drug discovery and the production of high-end complex generic injections. Its leading innovative candidate, LS001 (levo-demethyl-phencynonate hydrochloride), is currently in Phase II clinical trials for early and middle-stage Parkinson’s disease, while LS21031 is being developed as a selective PDE4D modulator for depressive disorders. Lansson maintains an integrated business model with an R&D hub in Beijing and a manufacturing base in Shandong, where it produces approved high-end products such as Sugammadex Sodium and Dexmedetomidine Hydrochloride using advanced formulation technologies like medium-and-long-chain fat emulsions.